Skip to main content
Top
Published in: Applied Health Economics and Health Policy 2/2013

01-04-2013 | Original Research Article

Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments

Authors: Bonny Parkinson, Stephen Goodall, Richard Norman

Published in: Applied Health Economics and Health Policy | Issue 2/2013

Login to get access

Abstract

Background

Economic evaluation of mandatory health programmes generally do not consider the utility impact of a loss of consumer choice upon implementation, despite evidence suggesting that consumers do value having the ability to choose.

Objectives

The primary aim of this study was to explore whether the utility impact of a loss of consumer choice from implementing mandatory health programmes can be measured using discrete choice experiments (DCEs).

Methods

Three case studies were used to test the methodology: fortification of bread-making flour with folate, mandatory influenza vaccination of children, and the banning of trans-fats. Attributes and levels were developed from a review of the literature. An orthogonal, fractional factorial design was used to select the profiles presented to respondents to allow estimation of main effects. Overall, each DCE consisted of 64 profiles which were allocated to four versions of 16 profiles. Each choice task compared two profiles, one being voluntary and the other being mandatory, plus a ‘no policy’ option, thus each respondent was presented with eight choice tasks. For each choice task, respondents were asked which health policy they most preferred and least preferred. Data was analysed using a mixed logit model with correlated coefficients (200 Halton draws). The compensating variation required for introducing a programme on a mandatory basis (versus achieving the same health impacts with a voluntary programme) that holds utility constant was estimated.

Results

Responses were provided by 535 participants (a response rate of 83 %). For the influenza vaccination and folate fortification programmes, the results suggested that some level of compensation may be required for introducing the programme on a mandatory basis. Introducing a mandatory influenza vaccination programme required the highest compensation (Australian dollars [A$] 112.75, 95 % CI −60.89 to 286.39) compared with folate fortification (A$18.05, 95 % CI −3.71 to 39.80). No compensation was required for introducing the trans-fats programme (−A$0.22, 95 % CI −6.24 to 5.80) [year 2010 values]. In addition to the type of mandatory health programme, the compensation required was also found to be dependent on a number of other factors. In particular, the study found an association between the compensation required and stronger libertarian preferences.

Conclusions

DCEs can be used to measure the utility impact of a loss of consumer choice. Excluding the utility impact of a loss of consumer choice from an economic evaluation taking a societal perspective may result in a sub-optimal, or incorrect, funding decision.
Appendix
Available only for authorised users
Footnotes
1
In Australia, 11 % of women aged 18–49 years consumed folate supplements in 2001.
 
2
Based on a 4^8 and 8^1 orthogonal array, with one attribute converted to a 2-level attribute, and the attributes not used removed: five 4-level attributes for the folate fortification and banning trans-fats DCEs, and three 4-level attributes for the influenza vaccination DCE.
 
3
The shift generators were 1113 and 1335 for the folate fortification and banning trans-fats DCEs, and 1111113 and 1333315 for the influenza vaccination DCE.
 
4
Is mandatory preferred to voluntary? Is voluntary preferred to mandatory? Is mandatory preferred to no policy? Is no policy preferred to mandatory? Is voluntary preferred to no policy? Is no policy preferred to voluntary?
 
5
Note that the latest Pharmaceutical Benefits Advisory Committee (PBAC) guidelines for Australia suggest that PBAC prefers a health system perspective over a societal perspective.
 
Literature
1.
go back to reference Productivity Commission. Impacts of advances in medical technology in Australia, Research Report. Melbourne: Productivity Commission; 2005. Productivity Commission. Impacts of advances in medical technology in Australia, Research Report. Melbourne: Productivity Commission; 2005.
4.
go back to reference Segal L, Dalziel K, Katz R. Informing a strategy for increasing folate levels to prevent neural tube defects: a cost-effectiveness analysis of options: a report for Food Standards Australia and New Zealand, Monash University and University of South Australia, ed. Food Standards Australia and New Zealand; 2007. Segal L, Dalziel K, Katz R. Informing a strategy for increasing folate levels to prevent neural tube defects: a cost-effectiveness analysis of options: a report for Food Standards Australia and New Zealand, Monash University and University of South Australia, ed. Food Standards Australia and New Zealand; 2007.
5.
go back to reference Access Economics. Cost benefit analysis of fortifying the food supply with iodine: Report for Food Standards Australia and New Zealand. Canberra: Access Economics; 2006. Access Economics. Cost benefit analysis of fortifying the food supply with iodine: Report for Food Standards Australia and New Zealand. Canberra: Access Economics; 2006.
6.
go back to reference Goodall S, Norman RP, Gallego G. Cost-effectiveness analysis of alternate strategies to address iodine deficiency in Australia, CHERE Project Report for the Department of Health and Ageing, Australian Government. Sydney: CHERE; 2007. p. 1–99. Goodall S, Norman RP, Gallego G. Cost-effectiveness analysis of alternate strategies to address iodine deficiency in Australia, CHERE Project Report for the Department of Health and Ageing, Australian Government. Sydney: CHERE; 2007. p. 1–99.
7.
go back to reference Parkinson B, Goodall S. Considering consumer choice in the economic evaluation of mandatory health programmes: a review. Health Policy. 2011;101(3):236–44.PubMedCrossRef Parkinson B, Goodall S. Considering consumer choice in the economic evaluation of mandatory health programmes: a review. Health Policy. 2011;101(3):236–44.PubMedCrossRef
9.
go back to reference Beauchamp T, Childress J. Principles of biomedical ethics. 4th ed. New York: Oxford University Press; 1996. Beauchamp T, Childress J. Principles of biomedical ethics. 4th ed. New York: Oxford University Press; 1996.
10.
go back to reference Wagstaff A, van Doorslaer E. Equity in health care finance and delivery. In: Culyer A, Newhouse J, editors. Handbook of health economics. Oxford: Elsevier; 2000. Wagstaff A, van Doorslaer E. Equity in health care finance and delivery. In: Culyer A, Newhouse J, editors. Handbook of health economics. Oxford: Elsevier; 2000.
11.
go back to reference Nozick R. Anarchy, state, and utopia. New York: Basic Books; 1975. Nozick R. Anarchy, state, and utopia. New York: Basic Books; 1975.
12.
go back to reference Williams A, Cookson R. Equity in Health. In: Culyer A, Newhouse J, editors. Handbook of health economics. Oxford: Elsevier; 2000. Williams A, Cookson R. Equity in Health. In: Culyer A, Newhouse J, editors. Handbook of health economics. Oxford: Elsevier; 2000.
13.
go back to reference Brouwer W, van Exel N, van den Berg B, van den Bos G, Koopmanschap M. Process utility from providing informal care: the benefit of caring. Health Policy. 2005;74(1):85–99.PubMedCrossRef Brouwer W, van Exel N, van den Berg B, van den Bos G, Koopmanschap M. Process utility from providing informal care: the benefit of caring. Health Policy. 2005;74(1):85–99.PubMedCrossRef
14.
go back to reference Sen A. Development as freedom. Oxford: Oxford University Press; 1999. Sen A. Development as freedom. Oxford: Oxford University Press; 1999.
15.
go back to reference Thaler R, Shefrin H. An economic theory of self-control. J Polit Econ. 1981;89(2):392–406.CrossRef Thaler R, Shefrin H. An economic theory of self-control. J Polit Econ. 1981;89(2):392–406.CrossRef
16.
go back to reference Lancaster K. A new approach to consumer theory. J Polit Econ. 1966;74(2):132.CrossRef Lancaster K. A new approach to consumer theory. J Polit Econ. 1966;74(2):132.CrossRef
17.
go back to reference Ryan M, Gerard K, Currie G. Using discrete choice experiments in health economics. In: Jones A, editor. The Elgar companion to health economics. Cheltenham: Edward Elgar Publishing Ltd; 2006. p. 405–14. Ryan M, Gerard K, Currie G. Using discrete choice experiments in health economics. In: Jones A, editor. The Elgar companion to health economics. Cheltenham: Edward Elgar Publishing Ltd; 2006. p. 405–14.
18.
go back to reference Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003;2(1):55–64.PubMed Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003;2(1):55–64.PubMed
19.
go back to reference Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory. Health Econ. 2004;13(9):901–7.PubMedCrossRef Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory. Health Econ. 2004;13(9):901–7.PubMedCrossRef
20.
go back to reference Ryan M. Deriving welfare measures in discrete choice experiments: a comment to Lanscar and Savage (I). Health Econ. 2004;13:909–12.PubMedCrossRef Ryan M. Deriving welfare measures in discrete choice experiments: a comment to Lanscar and Savage (I). Health Econ. 2004;13:909–12.PubMedCrossRef
21.
go back to reference Santos Silva J. Deriving welfare measures in discrete choice experiments: a comment to Lancsar and Savage (2). Health Econ. 2004;13(9):913–8 (discussion 9–24). Santos Silva J. Deriving welfare measures in discrete choice experiments: a comment to Lancsar and Savage (2). Health Econ. 2004;13(9):913–8 (discussion 9–24).
22.
go back to reference Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: a response to Ryan and Santos Silva. Health Econ. 2004;13(9):919–24.CrossRef Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: a response to Ryan and Santos Silva. Health Econ. 2004;13(9):919–24.CrossRef
23.
go back to reference Mark T, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Econ. 2004;13:563–73.PubMedCrossRef Mark T, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Econ. 2004;13:563–73.PubMedCrossRef
24.
go back to reference Australian Bureau of Statistics, Occasional paper: Measuring dietary habits in the 2001 National Health Survey, 4814.0.55.001. Canberra: ABS; 2003. Australian Bureau of Statistics, Occasional paper: Measuring dietary habits in the 2001 National Health Survey, 4814.0.55.001. Canberra: ABS; 2003.
25.
go back to reference Abeywardana S, Sullivan E. Neural tube defects in Australia: an epidemiological report. Cat. no. PER 45. Sydney: AIHW National Perinatal Statistics Unit; 2008. Abeywardana S, Sullivan E. Neural tube defects in Australia: an epidemiological report. Cat. no. PER 45. Sydney: AIHW National Perinatal Statistics Unit; 2008.
26.
go back to reference Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369–73.PubMedCrossRef Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190:1369–73.PubMedCrossRef
27.
go back to reference Piedra P, Gaglani M, Kozinetz C, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005;23(13):1540–8.PubMedCrossRef Piedra P, Gaglani M, Kozinetz C, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005;23(13):1540–8.PubMedCrossRef
28.
go back to reference Tuckerman J, Rajesh S, Oeppen C, et al. Review of the evidence of the effectiveness and cost effectiveness of interventions to address differences in the uptake of immunisations (including targeted vaccines) in people younger than 19 years: synopsis for consultation 24 September–22 October 2008. London: National Collaborating Centre for Women’s and Children’s Health; 2008. Tuckerman J, Rajesh S, Oeppen C, et al. Review of the evidence of the effectiveness and cost effectiveness of interventions to address differences in the uptake of immunisations (including targeted vaccines) in people younger than 19 years: synopsis for consultation 24 September–22 October 2008. London: National Collaborating Centre for Women’s and Children’s Health; 2008.
29.
go back to reference Hall J, Kenny P, King M, Louvier J, Viney R, Yeoh A. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination. Health Econ. 2002;2002(11):457–65.CrossRef Hall J, Kenny P, King M, Louvier J, Viney R, Yeoh A. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination. Health Econ. 2002;2002(11):457–65.CrossRef
30.
go back to reference Bentley T, Weinstein M, Willett W, Kuntz K. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr. 2009;12(4):455–67.PubMedCrossRef Bentley T, Weinstein M, Willett W, Kuntz K. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr. 2009;12(4):455–67.PubMedCrossRef
32.
go back to reference Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet. 2005;365(9461):773–80.PubMedCrossRef Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet. 2005;365(9461):773–80.PubMedCrossRef
33.
go back to reference ATAGI. Influenza. In: The Australian immunisation handbook. Canberra: Department of Health and National Health and Medical Research Council; 2008. p. 184–94. ATAGI. Influenza. In: The Australian immunisation handbook. Canberra: Department of Health and National Health and Medical Research Council; 2008. p. 184–94.
34.
go back to reference Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds W. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26:5321–30.PubMedCrossRef Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds W. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26:5321–30.PubMedCrossRef
35.
go back to reference Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Communicable Diseases Intelligence, Australian Department of Health and Ageing. 2007;31(Suppl.):viii-S152. Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Communicable Diseases Intelligence, Australian Department of Health and Ageing. 2007;31(Suppl.):viii-S152.
36.
go back to reference Mozaffarian D, Katan M, Ascherio A, Stampfer M, Willett W. Trans fatty acids and cardiovascular disease. New Eng J Med. 2006;354(15):1601.PubMedCrossRef Mozaffarian D, Katan M, Ascherio A, Stampfer M, Willett W. Trans fatty acids and cardiovascular disease. New Eng J Med. 2006;354(15):1601.PubMedCrossRef
38.
go back to reference Dixon S, Shackley P. Estimating the benefits of community water fluoridation using the willingness-to-pay technique: results of a pilot study. Commun Dent Oral Epidemiol. 1999;27:124–9.CrossRef Dixon S, Shackley P. Estimating the benefits of community water fluoridation using the willingness-to-pay technique: results of a pilot study. Commun Dent Oral Epidemiol. 1999;27:124–9.CrossRef
39.
go back to reference Dixon S, Shackley P. The use of willingness to pay to assess public preferences towards the fortification of foodstuffs with folic acid. Health Expect. 2003;6:140–8.PubMedCrossRef Dixon S, Shackley P. The use of willingness to pay to assess public preferences towards the fortification of foodstuffs with folic acid. Health Expect. 2003;6:140–8.PubMedCrossRef
42.
go back to reference McFadden D. Conditional logit analysis of qualitative choice behaviour. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 105–42. McFadden D. Conditional logit analysis of qualitative choice behaviour. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 105–42.
43.
go back to reference McFadden D, Train K. Mixed MNL models for discrete response. J Appl Econ. 2000;15:447–70.CrossRef McFadden D, Train K. Mixed MNL models for discrete response. J Appl Econ. 2000;15:447–70.CrossRef
44.
go back to reference Fiebig D, Keane M, Louvier J, Wasi N. The generalized multinomial logit model: accounting for scale and coefficient heterogeneity. Market Sci. 2010;29(3):393–421.CrossRef Fiebig D, Keane M, Louvier J, Wasi N. The generalized multinomial logit model: accounting for scale and coefficient heterogeneity. Market Sci. 2010;29(3):393–421.CrossRef
45.
go back to reference Train K. Discrete choice methods with simulation. 2nd ed. Cambridge: Cambridge University Press; 2009.CrossRef Train K. Discrete choice methods with simulation. 2nd ed. Cambridge: Cambridge University Press; 2009.CrossRef
46.
go back to reference Lancsar E, Louviere J. Deleting ‘irrational’ responses from discrete choice experiments: a case of investigating or imposing preferences? Health Econ. 2006;15(8):797–811.PubMedCrossRef Lancsar E, Louviere J. Deleting ‘irrational’ responses from discrete choice experiments: a case of investigating or imposing preferences? Health Econ. 2006;15(8):797–811.PubMedCrossRef
47.
go back to reference Flynn T. Using conjoint analysis and choice experiments to estimate QALY values: issues to consider. Pharmacoeconomics. 2010;28(9):711–22.PubMedCrossRef Flynn T. Using conjoint analysis and choice experiments to estimate QALY values: issues to consider. Pharmacoeconomics. 2010;28(9):711–22.PubMedCrossRef
48.
go back to reference Baker R, Bateman I, Donaldson C, et al. Weighting and valuing quality adjusted life years: preliminary results from the Social Value of a QALY Project. Newcastle: Institute of Health and Society, Newcastle University; 2008. Baker R, Bateman I, Donaldson C, et al. Weighting and valuing quality adjusted life years: preliminary results from the Social Value of a QALY Project. Newcastle: Institute of Health and Society, Newcastle University; 2008.
49.
go back to reference Shackley P, Dixon S. Using contingent valuation to elicit public preferences for water fluoridation. Appl Econ. 2000;32:777–87.CrossRef Shackley P, Dixon S. Using contingent valuation to elicit public preferences for water fluoridation. Appl Econ. 2000;32:777–87.CrossRef
50.
go back to reference Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. In: CHE Research Paper 54. York: The University of York, Centre for Health Economics; 2010. Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. In: CHE Research Paper 54. York: The University of York, Centre for Health Economics; 2010.
51.
go back to reference Pharmaceutical Benefits Advisory Committee, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Australian Government, Department of Health and Ageing; 2008. Pharmaceutical Benefits Advisory Committee, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Australian Government, Department of Health and Ageing; 2008.
52.
go back to reference National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
53.
go back to reference HM Treasury. The green book: appraisal and evaluation in central government. London: TSO; 2003. HM Treasury. The green book: appraisal and evaluation in central government. London: TSO; 2003.
54.
go back to reference Office of Best Practice Regulation (OBPR). Best practice regulation handbook. Canberra: Australian Government; 2007. Office of Best Practice Regulation (OBPR). Best practice regulation handbook. Canberra: Australian Government; 2007.
55.
go back to reference Australian Bureau of Statistics. Population by age and sex, Australian states and territories, 3201.0. Canberra: ABS; 2009. Australian Bureau of Statistics. Population by age and sex, Australian states and territories, 3201.0. Canberra: ABS; 2009.
56.
go back to reference Australian Bureau of Statistics, Aspects of social capital, 4911.0. Canberra: ABS; 2006. Australian Bureau of Statistics, Aspects of social capital, 4911.0. Canberra: ABS; 2006.
57.
go back to reference Australian Bureau of Statistics, Labour force, 6202.0. Canberra: ABS; 2010. Australian Bureau of Statistics, Labour force, 6202.0. Canberra: ABS; 2010.
58.
go back to reference Australian Bureau of Statistics, Family characteristics and transitions, 4442.0 Canberra: ABS; 2006–2007. Australian Bureau of Statistics, Family characteristics and transitions, 4442.0 Canberra: ABS; 2006–2007.
59.
go back to reference Australian Bureau of Statistics, Education and work, Australia, 6227.0. Canberra: ABS; 2008. Australian Bureau of Statistics, Education and work, Australia, 6227.0. Canberra: ABS; 2008.
60.
go back to reference Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev. 2001(3). Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev. 2001(3).
61.
go back to reference Food Standards Australia New Zealand. Intakes of trans fatty acids in New Zealand and Australia: Review Report, Item 3.6. Canberra: FSANZ; 2008. Food Standards Australia New Zealand. Intakes of trans fatty acids in New Zealand and Australia: Review Report, Item 3.6. Canberra: FSANZ; 2008.
Metadata
Title
Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments
Authors
Bonny Parkinson
Stephen Goodall
Richard Norman
Publication date
01-04-2013
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 2/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0017-1

Other articles of this Issue 2/2013

Applied Health Economics and Health Policy 2/2013 Go to the issue